Brokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $10.00

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been given an average rating of “Hold” by the nine ratings firms that are presently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $10.00.

A number of brokerages have issued reports on ZNTL. Guggenheim decreased their price target on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, November 15th. Finally, Oppenheimer restated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th.

Zentalis Pharmaceuticals Price Performance

NASDAQ:ZNTL opened at $3.06 on Tuesday. The company’s fifty day moving average price is $3.34 and its 200-day moving average price is $3.68. Zentalis Pharmaceuticals has a 1-year low of $2.66 and a 1-year high of $18.07. The firm has a market capitalization of $218.07 million, a P/E ratio of -1.23 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.36. Equities analysts anticipate that Zentalis Pharmaceuticals will post -2.48 EPS for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC lifted its stake in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after acquiring an additional 15,597 shares during the last quarter. Quarry LP acquired a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth approximately $55,000. Paloma Partners Management Co purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $37,000. Finally, Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals in the 3rd quarter valued at $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.